Your browser doesn't support javascript.
Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers.
Kale, Pratibha; Gupta, Ekta; Bihari, Chhagan; Patel, Niharika; Rooge, Sheetalnath; Pandey, Amit; Bajpai, Meenu; Khillan, Vikas; Chattopadhyay, Partha; Devi, Priti; Maurya, Ranjeet; Jha, Neha; Mehta, Priyanka; Kumar, Manish; Sharma, Pooja; Saifi, Sheeba; Swaminathan, Aparna; Alam, Sarfaraz; Uppili, Bharathram; Faruq, Mohammed; Agrawal, Anurag; Pandey, Rajesh; Sarin, Shiv Kumar.
  • Kale P; Department of Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Gupta E; Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Bihari C; Department of Hepatopathology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Patel N; Department of Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Rooge S; Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Pandey A; Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Bajpai M; Department of Transfusion Medicine, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Khillan V; Department of Clinical Microbiology, Institute of Liver and Biliary Sciences, New Delhi 110070, India.
  • Chattopadhyay P; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Devi P; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad 201002, India.
  • Maurya R; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Jha N; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad 201002, India.
  • Mehta P; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Kumar M; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad 201002, India.
  • Sharma P; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Saifi S; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Swaminathan A; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Alam S; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad 201002, India.
  • Uppili B; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Faruq M; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad 201002, India.
  • Agrawal A; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Pandey R; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
  • Sarin SK; Council for Scientific and Industrial Research CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India.
Vaccines (Basel) ; 10(1)2021 Dec 31.
Article in English | MEDLINE | ID: covidwho-1580341
ABSTRACT
This study elucidated the clinical, humoral immune response and genomic analysis of vaccine breakthrough (VBT) infections after ChAdOx1 nCoV-19/Covishield vaccine in healthcare workers (HCWs). Amongst 1858 HCWs, 1639 had received either two doses (1346) or a single dose (293) of ChAdOx1 nCoV-19 vaccine. SARS-CoV-2 IgG antibodies and neutralizing antibodies were measured in the vaccinated group and the development of SARS-CoV-2 infection was monitored.Forty-six RT-PCR positive samples from the 203 positive samples were subjected to whole genome sequencing (WGS). Of the 203 (10.92%) infected HCWs, 21.46% (47/219) were non-vaccinated, which was significantly more than 9.52% (156/1639) who were vaccinated and infection was higher in doctors and nurses. Unvaccinated HCWs had 1.57 times higher risk compared to partially vaccinated HCWs and 2.49 times higher risk than those who were fully vaccinated.The partially vaccinated were at higher risk than the fully vaccinated (RR 1.58). Antibody non-response was seen in 3.44% (4/116), low antibody levels in 15.51% (18/116) and medium levels were found in 81.03% (94/116). Fully vaccinated HCWs had a higher antibody response at day 42 than those who were partially vaccinated (8.96 + 4.00 vs. 7.17 + 3.82). Whole genome sequencing of 46 samples revealed that the Delta variant (B.1.617.2) was predominant (69.5%). HCWs who had received two doses of vaccine showed better protection from mild, moderate, or severe infection, with a higher humoral immune response than those who had received a single dose. The genomic analysis revealed the predominance of the Delta variant (B.1.617.2) in the VBT infections.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines10010054

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines10010054